Recombinant Human Receptor-Type Tyrosine-Protein Kinase Flt3 (FLT3) Protein (His)

• Purity: Greater than 90% as determined by SDS-PAGE.
• Host Species: Human
• Accession: P36888
• Gene: FLT3
• CAT.NO: B000035
• Product Name: Recombinant Human Receptor-Type Tyrosine-Protein Kinase Flt3 (FLT3) Protein (His)
• Source: E.coli
• Protein Expression Range: 564-958aa
• Tag: N-10His
• Molecular Mass: 49.3 kDa
• Form: Liquid or Lyophilized powder
• Buffer: Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
• Storage: 1. Store at -20¡«C/-80¡«C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4¡«C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20¡«C/-80¡«C. Protein in lyophilized powder form is stable for up to 12 months at -20¡«C/-80¡«C.

Tyrosine-protein kinase FLT3 functions as a cell-surface receptor for the cytokine FLT3 ligand (FLT3LG), playing a pivotal role in the differentiation, proliferation, and survival of hematopoietic progenitor and dendritic cells. Upon activation, FLT3 promotes phosphorylation of SHC1 and AKT1, triggering downstream effectors such as MTOR. It also activates RAS signaling, leading to the phosphorylation of MAPK1/ERK2 and MAPK3/ERK1, and promotes phosphorylation of proteins including FES, FER, PTPN6/SHP-1, PTPN11/SHP-2, PLCG1, and STAT5A/B. Wild-type FLT3 activation marginally stimulates STAT5 signaling, whereas mutations inducing constitutive kinase activity drive uncontrolled cell proliferation and resistance to apoptosis by activating multiple pathways. These properties underline FLT3’s importance in normal hematopoiesis and its role in the pathogenesis of hematological malignancies, making it a crucial therapeutic target.